Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13348MR)

This product GTTS-WQ13348MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13348MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13363MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ15793MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ14576MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ8611MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ7909MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ2443MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ14167MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ5388MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW